Analyst Ratings For Knight Therapeutics (TSE:GUD)
Today, Scotiabank raised its price target on Knight Therapeutics (TSE:GUD) to C$11.00 per share.
There are 2 hold ratings, 3 buy ratings on the stock.
The current consensus rating on Knight Therapeutics (TSE:GUD) is Buy (Score: 2.60) with a consensus target price of C$11.16 per share, a potential .
Some recent analyst ratings include
- 3/14/2017-TD Securities Reiterated Rating of Buy.
- 1/4/2017-Mackie was Downgraded by analysts at Mackie from a “Buy ” rating to a ” Hold” rating. They now have a C$10.75 price target on the stock, up previously from C$12.00 .
- 11/10/2016-Bloom Burton Reiterated Rating of Accumulate.
About Knight Therapeutics (TSE:GUD)
Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.
Recent Trading Activity for Knight Therapeutics (TSE:GUD)
Shares of Knight Therapeutics closed the previous trading session at 10.20 down -0.17 -1.64% with 570,616 shares trading hands.
